Back to Search Start Over

A reference human induced pluripotent stem cell line for large-scale collaborative studies.

Authors :
Pantazis CB
Yang A
Lara E
McDonough JA
Blauwendraat C
Peng L
Oguro H
Kanaujiya J
Zou J
Sebesta D
Pratt G
Cross E
Blockwick J
Buxton P
Kinner-Bibeau L
Medura C
Tompkins C
Hughes S
Santiana M
Faghri F
Nalls MA
Vitale D
Ballard S
Qi YA
Ramos DM
Anderson KM
Stadler J
Narayan P
Papademetriou J
Reilly L
Nelson MP
Aggarwal S
Rosen LU
Kirwan P
Pisupati V
Coon SL
Scholz SW
Priebe T
Öttl M
Dong J
Meijer M
Janssen LJM
Lourenco VS
van der Kant R
Crusius D
Paquet D
Raulin AC
Bu G
Held A
Wainger BJ
Gabriele RMC
Casey JM
Wray S
Abu-Bonsrah D
Parish CL
Beccari MS
Cleveland DW
Li E
Rose IVL
Kampmann M
Calatayud Aristoy C
Verstreken P
Heinrich L
Chen MY
Schüle B
Dou D
Holzbaur ELF
Zanellati MC
Basundra R
Deshmukh M
Cohen S
Khanna R
Raman M
Nevin ZS
Matia M
Van Lent J
Timmerman V
Conklin BR
Johnson Chase K
Zhang K
Funes S
Bosco DA
Erlebach L
Welzer M
Kronenberg-Versteeg D
Lyu G
Arenas E
Coccia E
Sarrafha L
Ahfeldt T
Marioni JC
Skarnes WC
Cookson MR
Ward ME
Merkle FT
Source :
Cell stem cell [Cell Stem Cell] 2022 Dec 01; Vol. 29 (12), pp. 1685-1702.e22.
Publication Year :
2022

Abstract

Human induced pluripotent stem cell (iPSC) lines are a powerful tool for studying development and disease, but the considerable phenotypic variation between lines makes it challenging to replicate key findings and integrate data across research groups. To address this issue, we sub-cloned candidate human iPSC lines and deeply characterized their genetic properties using whole genome sequencing, their genomic stability upon CRISPR-Cas9-based gene editing, and their phenotypic properties including differentiation to commonly used cell types. These studies identified KOLF2.1J as an all-around well-performing iPSC line. We then shared KOLF2.1J with groups around the world who tested its performance in head-to-head comparisons with their own preferred iPSC lines across a diverse range of differentiation protocols and functional assays. On the strength of these findings, we have made KOLF2.1J and its gene-edited derivative clones readily accessible to promote the standardization required for large-scale collaborative science in the stem cell field.<br />Competing Interests: Declaration of interests S.W.S. is on the scientific advisory council of the Lewy Body Dementia Association and the MSA Coalition. S.W.S. is an editorial board member for the Journal of Parkinson Disease and JAMA Neurology. S.W.S. received research support from Cerevel Therapeutics. M.K. serves on the scientific advisory boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, and Alector and is a consultant to Modulo Bio and Recursion Therapeutics. Participation by researchers from Data Tecnica International, LLC in this project was part of a competitive contract awarded to Data Tecnica International, LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc. E.A. is founder, shareholder, and scientific advisor of Cholestenix, Ltd.<br /> (Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1875-9777
Volume :
29
Issue :
12
Database :
MEDLINE
Journal :
Cell stem cell
Publication Type :
Academic Journal
Accession number :
36459969
Full Text :
https://doi.org/10.1016/j.stem.2022.11.004